9/27/2022  10:17:28 AM Chg. +0.25 Volume Bid10:22:01 AM Ask10:22:01 AM Market Capitalization Dividend Y. P/E Ratio
58.55CHF +0.43% 5,365
Turnover: 313,612.18
58.35Bid Size: 25 58.50Ask Size: 63 4.1 bill.CHF 1.20% 36.16

Business description

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.
 

Management board & Supervisory board

CEO
Thomas Meier
Management board
Alain Schaffter, Dr. Anne-Kathrin Stoller, Dr. Günther Loidl, Roland Schürmann
Supervisory board
Dr. Kuno Sommer, Dr. Alex Fässler, Dr. h.c. Peter Grogg, Dr. Steffen Lang, Nicole Grogg Hötzer, Prof. Dr. Helma Wennemers
 

Company data

Name: Bachem Holding AG
Address: Hauptstraße 144,CH-4416 Bubendorf
Phone: +41-58-595-2020
Fax: +41-58-595-2040
E-mail: sales.ch@bachem.com
Internet: www.bachem.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 38.40%
IPO date: -

Investor relations

Name: -
IR phone: +41-58-595-2021
IR Fax: +41-58-595-2043
IR e-mail: ir@bachem.com

Company calendar

CW 10 | 3/7/2023 4th Quarter/Annual Report
CW 16 | 4/19/2023 General Shareholder Meeting
CW 30 | 7/27/2023 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

P. Grogg (über Ingro Finanz AG)
 
55.70%
Freefloat
 
38.40%
Familie P. Grogg
 
5.90%